Acacia Pharma is a commercial stage biopharmaceuticall group focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy. The Group has identified important and commercially attractive unmet needs in nausea & vomiting and procedural sedation, and has two approved products and a late-stage development candidate in its portfolio designed to meet those needs.
BARHEMSYS® is approved in the US (February 2020) for the treatment and prophylaxis of postoperative nausea & vomiting (PONV), either alone or in combination other antiemetics. US launch is planned for 2H 2020.
BYFAVO™ is a very rapid onset/offset IV benzodiazepine sedative approved in the US (July 2020) for use during invasive medical procedures lasting 30 minutes or less, such as colonoscopy and bronchoscopy. US launch is planned in 2H 2020. BYFAVO is in-licensed from Cosmo Pharmaceuticals for the US market.
The Group’s pipeline also includes APD403 for chemotherapy induced nausea & vomiting (CINV). APD403 is based on the selective dopamine antagonist amisulpride, the same active ingredient as in BARHEMSYS. It is being developed in both intravenous and oral form and has successfully completed Phase 2 testing in patients receiving highly emetogenic chemotherapy.
Acacia Pharma plans to commercialize its products directly in the US through its own commercial operations targeting anaesthesiologists and oncologists. Acacia Pharma intends to establish licensing and/or distribution agreements with selected pharmaceutical partners outside the US.
The Company’s management team and Board have extensive experience in the discovery, development and commercialization of hospital pharmaceutical products.
Acacia Pharma has offices in Cambridge, UK and Indianapolis, IN, USA, and is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.